Associate Professor, Medicine, University of Wisconsin Medical School
Oncology
Dr. Glenn Liu, MD
|
|
Give Review
Doctor Glenn Liu, MD is an expert in the field of Oncology. He went to Jefferson Medical College. He received 1 awards: "Meaningful Use Stage 1 Certification". Dr. Glenn Liu is a published MD as well. He has 24 publications published. The latest was: A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Doctor Glenn Liu, MD accepts Medicare.
Publications
- A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid Tumors.
- A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prost...
- A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate Cancer.
- A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate Cancer (CRPC)-a ...
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of (131)I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.
- PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-labeled Ramucirumab.
- Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate Cancers with osseous metastases.
- A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid Tumors.
- A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced Cancer.
- Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase (PAP) in Patients with Castration-Resistant Prostate Cancer.
- A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell Carcinoma and other advanced solid malignancies.
- A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation T...
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung Cancer.
- A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate Cancer.
- Intermittent versus continuous androgen deprivation in prostate Cancer.
- High resolution ultrasound features of prostatic rib metastasis: A prospective feasibility study with implication in the high-risk prostate Cancer patient.
- Imaging of castration-resistant prostrate Cancer: development of imaging response biomarkers.
- Current controversies in the management of biochemical failure in prostate Cancer.
- WE-C-BRA-07: Assessment of Heterogeneous Treatment Response in Patients with Multiple Solid Tumors.
- SU-E-J-194: The Impact of Different Imaging Measures on Treatment Response Assessment of Bone Metastases.
- Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate Cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
- Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) ...
- A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal Cancer.
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
University Wisc Hospital And Clins
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Wisconsin -
Jefferson Medical College
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER | 1629039078 | |
| NPPES Provider LastName | LIU | |
| NPPES Provider FirstName | GLENN | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 299.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629039078 |
| Last Name Of The Provider | LIU |
| First Name Of The Provider | GLENN |
| View All |
Similar Doctors
|
|
Dr. Shannon E. O'Mahar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark R. Albertini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Diggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel L. Mulkerin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amye J. Tevaarwerk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kari B. Wisinski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua M. Lang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy P. Cetnar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George Wilding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas G. McNeel, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|